Sulpiride augmentation for schizophrenia

Schizophrenia Bulletin

Volumn 36, Issue 2, 2010, Pages 229-230

  Wang, Jijun ^a   Omori, Ichiro M ^b   Fenton, Mark ^c   Soares, Bernardo ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c Database of Uncertainties about the Effects of Treatments DUETs   (United Kingdom)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cochrane; Schizophrenia; Sulpiride

Indexed keywords

CLOZAPINE; SULPIRIDE;

ABDOMINAL DISTENSION; ANOREXIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERSALIVATION; META ANALYSIS; MONOTHERAPY; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SHORT SURVEY; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; LONG-TERM CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 77749254569     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp163     Document Type: Short Survey

References (1)

1. Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2009;(4): Art. No.: CD008125. doi: 10. 1002/14651858. CD008125.